Skip to main content
XOMA
NASDAQ Life Sciences

7.4亿美元收购:Ligand以每股39美元、2.9%溢价收购Xoma Royalty

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
9
Price
$39
Mkt Cap
$451.606M
52W Low
$22.29
52W High
$40.74
Market data snapshot near publication time

summarizeSummary

据The Wall Street Journal报道,Ligand Pharmaceuticals计划以大约7.4亿美元、或每股39美元现金收购Xoma Royalty。这项拟议的全现金交易代表了周五Xoma收盘价的2.9%溢价。该收购可能最早今日宣布,对Xoma Royalty来说是一件高度重要的事件,为股东提供了溢价退出,并从根本上改变了公司的未来。对于Ligand来说,这代表了其药品专利权资产的重大扩张。交易者将密切关注官方公告以及有关交易的任何进一步细节。

在该公告发布时,XOMA的交易价格为$39.00,交易所为NASDAQ,所属行业为Life Sciences,市值约为$4.5亿。 52周交易区间为$22.29至$40.74。 这则新闻被评估为积极市场情绪,重要性评分为9/10。 来源:Dow Jones Newswires。


show_chartPrice Chart

Share this article

Copied!

feed XOMA - Latest Insights

XOMA
Apr 27, 2026, 8:19 AM EDT
Filing Type: DEFA14A
Importance Score:
10
XOMA
Apr 27, 2026, 8:16 AM EDT
Filing Type: 8-K
Importance Score:
10
XOMA
Apr 27, 2026, 6:12 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
XOMA
Mar 30, 2026, 5:32 PM EDT
Filing Type: DEF 14A
Importance Score:
7
XOMA
Mar 18, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
XOMA
Mar 02, 2026, 6:04 AM EST
Filing Type: 8-K
Importance Score:
8
XOMA
Feb 09, 2026, 4:19 PM EST
Filing Type: 8-K
Importance Score:
8
XOMA
Feb 02, 2026, 4:33 PM EST
Filing Type: 8-K/A
Importance Score:
7
XOMA
Jan 15, 2026, 4:25 PM EST
Filing Type: 8-K
Importance Score:
8